POLARx™ Cardiac Cryoablation System Post Market Clinical Study (POLAR SMART)

计划入组 295 人 · 首次发布于 2022 年 3 月 16 日

POLARx Post Approval Study (POLARx PAS)

计划入组 200 人 · 首次发布于 2023 年 12 月 14 日

POLARx Cardiac Cryoablation System Study

计划入组 400 人 · 首次发布于 2020 年 1 月 31 日

Polaris

Polaris program (undisclosed inflammatory indication)

Polaryx Therapeutics, Inc.

United States

Polares Medical SA

Switzerland

Polaryx Therapeutics Secures Nasdaq Listing Ahead of Phase 2 Trial for Rare Lysosomal Storage Disorders

How Basket Trials Are Reshaping Drug Development Timelines for Rare Pediatric Diseases

Protaryx Medical Receives FDA 510(k) Clearance for Transseptal Puncture Device